Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Vivoryon Therapeutics N.V.
Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025
Halle (Saale) / Munich, Germany, June 6, 2025 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical stage company developing small molecule medicines for inflammatory and fibrotic disorders, with a primary focus on kidney diseases, today announced that meta-analysis data for its lead drug in development, varoglutamstat, was presented at the 62nd ERA Congress of the European Renal Association in Vienna, Austria, today, June 6, 2025.
'We are delighted that the results of the Phase 2 program were accepted for presentation at the ERA 2025 congress. This allowed Vivoryon to share the outstanding improvements of varoglutamstat on kidney function (eGFR) with the scientific and medical expert community in the kidney space,' said Frank Weber, MD, CEO of Vivoryon.
Presentation Highlights
Varoglutamstat is a first-in-class glutaminyl cyclase (QPCT/L) inhibitor with potent anti-inflammatory and anti-fibrotic effects. VIVIAD and VIVA-MIND, two independent Phase 2 studies in the EU and U.S. showed a statistically significant and clinically meaningful improvement in a prospectively defined kidney function parameter, eGFR, in an elderly patient population. This improvement was consistent in both trials independently, replicated in the meta-analysis and pooled analysis, and provides converging evidence for this finding. Statistically significant differences between varoglutamstat and placebo were first observed at week 24 and were sustained until week 96. The meta-analysis also confirmed a substantially larger effect size in study participants with diabetes compared to those without diabetes.
The next step is planned to be a dedicated Phase 2b trial in patients with diabetic kidney disease (patients with diabetes and chronic kidney disease stage 3b/4). The main goal will be to investigate the efficacy on eGFR in this patient population and to obtain additional information on a potential effect on proteinuria and other kidney specific markers.
Presentation Details
Date: June 6, 2025
Presentation time: 8:15 am CEST as part of the focused oral session
Title: Varoglutamstat improves eGFR and offers a new approach to treat diabetic kidney disease (DKD): meta-analysis from two independent Phase 2 studies
Venue: Vienna, Austria
Presenter: Frank Weber, MD, CEO of Vivoryon Therapeutics
###
About Vivoryon Therapeutics N.V.
Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon's most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease. www.vivoryon.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Audien Atom Hearing Aid Releases 2025 Accessibility Update: Wireless Charging, Invisible Fit & Direct-to-Consumer Simplicity Reshape Hearing Aid Market
The 2025 update to the Atom One and Atom 2 models introduces enhanced wireless charging, Comfort+ miniaturization, and multi-mode support in response to growing demand for non-prescription, affordable hearing technology LOS ANGELES, June 28, 2025 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE Audien Hearing, a pioneering U.S.-based direct-to-consumer technology company, today announced its 2025 accessibility update for the Audien Atom Hearing Aid line. This update, driven by consumer needs and preferences, introduces innovative features such as non-prescription hearing support, wireless charging, and invisible in-ear design. As consumer behavior shifts towards self-managed wellness tools, Audien's direct-to-consumer solutions are gaining widespread interest across the tech-enabled hearing support landscape. With over one million customers served, the company's latest announcement addresses evolving demands for hearing aids that bypass traditional medical markups, require no prescriptions or fittings, and integrate effortlessly into daily life. The 2025 update, with its focus on affordability and accessibility, outlines specific improvements to the Atom One and Atom 2 models—both engineered for comfort, clarity, and cost transparency. What You'll Learn in This Accessibility Update Why demand for invisible, rechargeable hearing aids is increasing in 2025 How Audien Atom One and Atom 2 deliver performance without clinical pricing Where consumer search trends show growing interest in over-the-counter hearing support What new features like Atom Sound Technology™ and Comfort+ miniaturization mean for users How Audien aligns with the shift toward self-guided hearing wellness Hearing Aid Demand Surges as Consumers Seek Control, Clarity, and Simplicity More than 500 million people worldwide experience hearing loss, yet many remain underserved by traditional hearing aid models due to pricing, accessibility, or stigma. In 2025, hearing support is evolving from a clinical issue into a broader discussion about wellness and technology. Consumer behavior reflects this shift. Digital interest has grown substantially in phrases like "wireless hearing aids," "affordable hearing help," "hearing aid without prescription," and "invisible ear canal device." These keyword trends indicate a rising preference for performance, portability, and simplicity. Consumers are no longer willing to settle for outdated systems that require multi-step clinical approval and high out-of-pocket costs. Audien Hearing enters this market landscape with an accessibility-forward offering that aligns with these expectations: streamlined, rechargeable hearing support tools that consumers can order and use without medical consultations. The movement toward affordable, over-the-counter hearing wellness has found a foothold in the brand's direct-to-consumer strategy. 2025 Audien Product Announcement: Atom One and Atom 2 Offer Wireless and Minimalist Design Audien's 2025 update centers on its two flagship models: the Atom One and Atom 2. These devices are designed to provide non-prescription hearing support through technology-driven features that prioritize ease of use and affordability. Audien Atom One features: Compact design that fits discreetly into the ear canal Wireless magnetic USB-C charging Comfort+ ergonomics with a 20-hour battery life No prescription, fitting, or clinical visit is required Audien Atom 2 builds upon this foundation with: Four adjustable hearing modes for contextual use An extended battery duration Enhanced Comfort+ miniaturization for an improved fit Both models are part of Audien's broader goal to deliver accessible hearing amplification tools at a fraction of the traditional market price without compromising on usability or design. Atom One vs. Atom 2: Understanding the Differences and Use Case Scenarios The Atom One model is ideal for individuals seeking a low-maintenance, highly discreet solution for mild to moderate hearing support. Its ultra-compact form, simple magnetic charging, and streamlined single-mode amplification make it an excellent fit for first-time users or those prioritizing invisibility and ease of use in quiet or consistent environments. The Atom 2, meanwhile, expands on this offering with four distinct hearing modes. This added flexibility is designed for users who encounter a broader range of sound environments throughout the day, such as those working in public settings, teaching, or regularly transitioning between indoor and outdoor spaces. The extended battery life and upgraded Comfort+ fit also provide enhanced support for prolonged daily use. Both models are built around autonomy—removing the need for reprogramming, fitting appointments, or learning curves. The choice between them typically comes down to lifestyle, acoustic variability, and feature preferences. Rising Search Interest Reflects Market Shift Toward Self-Guided Hearing Solutions Across digital channels, interest in non-clinical hearing tools continues to expand. Search traffic has surged for key terms such as "rechargeable hearing aids," "invisible ear canal device," "affordable hearing help," "hearing aid without prescription," and "OTC hearing support 2025." These trends reveal a shift in consumer priorities, favoring autonomy, simplicity, and cost transparency over traditional in-clinic models. User forums and independent reviews consistently echo frustrations with legacy systems while spotlighting the appeal of modern, self-managed alternatives. The visibility of Audien Atom within these conversations signals not only product interest but a broader cultural embrace of hearing technology as a daily lifestyle accessory—comparable to fitness trackers or smart glasses—rather than a specialized clinical tool. Technology Spotlight: Inside the Audien Atom Series Audien's technical evolution is driven by consumer interest in modern wellness devices that provide clarity without complexity. The 2025 Atom product line is designed with user-friendliness in mind, featuring several core elements that ensure a seamless user experience: Atom Sound Technology™ This proprietary chip is designed to enhance speech clarity while minimizing ambient interference. It supports real-time speech amplification in environments where standard devices often struggle to function effectively. Magnetic Wireless Charging Architecture With USB-C wireless charging and 20–24-hour battery capacity, Audien devices eliminate the need for traditional hearing aid batteries. The portable charging case enhances convenience for travel and daily use. Comfort+ Miniaturization Design Both models prioritize discreet sizing and ergonomics. The Atom One is 22% smaller than previous iterations, enabling near-invisible wear that aligns with consumer expectations for subtlety and comfort. Multi-Mode Support (Atom 2 only) Four hearing modes provide customizable performance for various environments, from quiet indoor conversations to noisier public settings. This user-controlled feature enhances adaptability without requiring professional reprogramming. Together, these elements form a hearing solution designed for independent use—removing traditional barriers to auditory support and reframing what hearing devices can look and feel like in everyday life. User Journey and Market Reception The Audien Atom line has not only become a benchmark in the broader discussion about modern, self-directed hearing solutions, but it has also received overwhelmingly positive market reception. The public commentary reflects a shared desire for hearing support that avoids the burdens of clinic appointments and complex fittings. For many consumers—especially those exploring hearing devices for the first time—Audien offers a low-barrier entry point that feels accessible and intuitive. Recurring themes include: Preference for solutions that do not require hearing tests Appreciation for the plug-and-play nature of the Atom line The positive reception of the minimalist, invisible form factor Although some users voice skepticism regarding the effectiveness of low-cost hearing devices without personalization, others accept this trade-off in favor of convenience, discretion, and affordability. Hearing in Real Life: Consumer Profiles Reflect Use Across Ages and Lifestyles Audien's accessibility-forward approach is reflected in the diversity of its user base. A 62-year-old retiree in Arizona reported using the Atom One to comfortably engage in weekly book club meetings without feeling self-conscious. A 45-year-old elementary school teacher noted that the Atom 2 helped manage classroom acoustics by switching between noise-reduction modes throughout the school day. For younger users who may be sensitive to loud environments or early-stage hearing decline, the compact and wearable design offers seamless integration into everyday routines. Whether for navigating work meetings, family gatherings, or social events, the Atom line is being adopted by individuals seeking independence and functionality without a clinical label. These stories highlight the growing appeal of discreet, self-managed devices that serve both performance and lifestyle goals. Understanding the Regulatory Environment: Why Non-Prescription Hearing Aids Are Thriving Following the FDA's approval of over-the-counter (OTC) hearing aid sales in 2022, companies like Audien have gained traction by filling the gap between expensive medical devices and ineffective amplification gimmicks. The FDA's ruling opened the door for innovation and market competition, allowing consumers to access devices that support general hearing needs without navigating complex healthcare systems. In parallel, rising out-of-pocket healthcare costs have driven demand for self-managed wellness tools. As consumers take charge of their health journeys, the hearing aid category is benefiting from the same tailwinds as wearable fitness devices, vision correction platforms, and sleep optimization tools. Audien's product evolution reflects the influence of these macroeconomic and behavioral forces. Breaking Down the Cost Difference: Retail Models vs. Direct-to-Consumer Savings Traditional hearing aids can range from $3,000 to $7,000, often requiring multiple visits, tests, and service plans. These costs are frequently not covered by insurance and represent a significant financial burden for millions of consumers. Audien's direct-to-consumer approach eliminates intermediaries, showroom overhead, and the need for custom manufacturing. The result is a leaner, more transparent model that passes savings directly to users. Consumers pay a one-time cost for Atom One or Atom 2, with no contracts, subscriptions, or upsells. For individuals seeking mild to moderate hearing support, this model provides an opportunity to regain confidence in communication without incurring debt or navigating complex billing systems. Getting Started with Audien: What First-Time Users Can Expect New users can expect an intuitive setup experience. After unboxing, the devices can be fully charged using the included USB-C magnetic case in approximately 4 to 6 hours. Once charged, they are inserted directly into the ear canal and begin working immediately—no pairing, syncing, or calibration is required. Comfort and miniaturization ensure that users feel minimal pressure and visibility. Users are encouraged to wear the devices for short periods during the first few days to allow for a gentle adjustment period. Cleaning involves a soft brush or cloth, and a detailed maintenance guide is included for long-term care. The simplicity of this onboarding experience is one of Audien's most frequently cited advantages among first-time buyers. Direct Access and Consumer-Centric Availability Audien Atom Hearing Aids are available for purchase directly through the company's official website. The platform serves as both a product portal and an educational hub, offering instructional videos, specifications, and support materials to guide users through their experience. Key aspects of the direct-to-consumer model include: No prescription or audiologist consultation No clinic visit or retail markup Transparent product explanations with customer support access Audien does not provide diagnostic services or medical advice. Its offerings are wellness-aligned, non-clinical tools designed to enhance hearing clarity in ordinary daily situations. The company maintains compliance with consumer protection standards and clearly communicates the scope of its product applications. Final Observations: Hearing Wellness as a Lifestyle Choice The hearing support industry is evolving. Once viewed primarily as a domain of clinical intervention, hearing tools are now being reframed as part of the broader personal health and technology marketplace. Similar to shifts in vision correction, sleep optimization, and fitness tracking, the hearing space is embracing self-serve functionality and consumer-first accessibility. Audien's 2025 update reflects this transformation. With a focus on wireless charging, discreet design, and ease of use, the company's Atom series aligns with growing expectations for wellness products that are transparent, approachable, and compatible with modern life. These tools are not just for those with medical diagnoses—they're for anyone seeking more precise sound in everyday conversations. As awareness grows and consumer empowerment takes center stage, the Atom line may signal the future of how hearing wellness is delivered: directly, affordably, and without complexity. About Audien Hearing™ Audien Hearing™ is a U.S.-based wellness technology company focused on simplifying access to hearing support. Founded to address the cost and complexity of traditional hearing aids, Audien develops in-ear, rechargeable devices that emphasize user independence and design simplicity. All devices are offered through the company's online platform and are intended for non-clinical use. Audien does not provide diagnostic services or medical treatment. Its mission is to empower consumers to manage hearing support in a transparent, affordable, and approachable way. Contact Audien Hearing Email: info@ Website: Disclaimers This release contains general information only and does not constitute medical advice. The products referenced are not intended to diagnose, treat, cure, or prevent any disease. The Food and Drug Administration has evaluated no statements in this release. Individuals should consult with a qualified healthcare provider for any medical concerns. Results may vary by user. Audien Hearing does not provide audiological testing, clinical consultations, or professional medical services. CONTACT: Audien Hearing Email: info@ Website: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
3 hours ago
- Gizmodo
Elon Musk and Mark Zuckerberg Want to Control AI by Crushing ChatGPT's Father
The AI race was never going to be polite. But what's unfolding in Silicon Valley in 2025 looks more like Succession meets Black Mirror than a traditional tech rivalry. Forget code. This is about power, control, and a rapidly closing window to dominate the most transformative technology in history. At the center of the fight: three men, three worldviews, and one finish line. Let's break down the combatants. This one is personal and litigious. Musk and Altman co-founded OpenAI in 2015 as a nonprofit devoted to building safe, open-source artificial intelligence. But the bromance collapsed when Musk attempted to take control of the company in 2018 and failed. He left bitterly and has been attacking OpenAI ever since. In 2023, Musk sued OpenAI and Altman, accusing them of betraying the nonprofit's mission by aligning too closely with Microsoft and putting profit over safety. The lawsuit is still grinding through federal court. Among other things, it claims OpenAI's flagship product, ChatGPT, is a closed-source commercial weapon funded by Big Tech and wrapped in secrecy. Altman denies the betrayal and OpenAI has countersued. The legal drama is thick and both sides have subpoenaed internal documents. Meanwhile, Musk's xAI is developing its own ChatGPT rival and launching it on X (formerly Twitter). This is a very public and very expensive fight over who gets to define ethical AI. Stakes: Both want to build AGI, or Artificial General Intelligence, a system smarter than humans. Musk wants to do it his way with radical transparency and no corporate strings. Altman wants to do it with Microsoft money, oversight, and a mission-first approach. The future of AI safety and perhaps civilization is the prize. They were supposed to be on the same team. Microsoft has invested over $13 billion in OpenAI and uses ChatGPT to power Bing, Copilot, and Azure. But now the two companies are increasingly at odds and headed for a potential breach. Microsoft has quietly built its own internal AI team called MAI, which is developing foundation models independent of OpenAI. The company wants more control, fewer surprises, and possibly a total replacement. Altman, meanwhile, has turned OpenAI into a hybrid nonprofit-corporate juggernaut. He's building custom chips, launching an AI app store, and moving fast into hardware and enterprise services. Microsoft sees this as direct competition. It's a fraying marriage held together by mutual benefit, but barely. Stakes: A real split could upend the entire enterprise AI ecosystem and open the door for rivals like Google, Meta, or Anthropic to swoop in. This relationship could end with another courtroom clash. It's the quietest war but maybe the most cutthroat. Meta has made AI its top priority for 2025 and Zuckerberg is going straight for Altman's team. In recent months, Meta has offered $100 million and more in signing bonuses to OpenAI researchers in a bid to poach top talent, Altman says. So far, most have stayed loyal to Altman. But the scale of the offers has shocked the Valley. In a podcast with his brother, Altman didn't mince words: 'They started making these, like, giant offers to a lot of people on our team, you know, like $100 million signing bonuses,' Altman said, adding:'It is crazy.' He accused Meta of 'just trying to copy OpenAI, down to the UI mistakes.' Zuckerberg's strategy is familiar. Outspend, out-recruit, outlast. Meta's AI tools are still basic compared to ChatGPT, but with enough hires and acquisitions (like rumored talks with voice-AI startup PlayAI), Meta hopes to leapfrog the field. Stakes: Zuckerberg is fighting not just for dominance in AI, but for relevance. If Meta fails to catch up, it could be left behind in a world where AI, not social media, is the next major computing platform. New episode of Uncapped with @sama. Enjoy 🤗 — Jack Altman (@jaltma) June 17, 2025The AI race has become a war of personalities. Altman, the techno-missionary. Musk, the chaos capitalist. Zuckerberg, the empire builder. Each believes they are the only one who can lead humanity into the next era of intelligence. What's unfolding is a battle for the infrastructure of the 21st century: who owns the models, who trains the machines, and who gets to decide what AI thinks. And if the lawsuits, subpoenas, and poaching wars are any indication, they're willing to burn billions to win.
Yahoo
3 hours ago
- Yahoo
5 Cars With Trade-In Values So Low That They're Not Worth Selling
Trading in a car can seem like the easiest way to upgrade your ride, but for some models, the dealer's offer will feel like an insult. In 2025, several vehicles are facing such steep depreciation and low demand that their trade-in values are shockingly low. Lauren Fix, automotive expert at Car Coach Reports, explained that high depreciation, oversupply and expensive maintenance are the main reasons these cars are so undervalued. Find Out: Read Next: Dealers also factor in brand perception and the cost of reconditioning, which can slash offers even further. For many owners, the trade-in value might be lower than what they could get from a private sale or even scrapping the car. Here are five cars with trade-in values so low that selling them to a dealer just does not make financial sense for most owners. Also consider these five cars are worth trading in for a newer model. The Jaguar I-PACE, an electric SUV launched with high hopes, now leads the pack in five-year depreciation, losing about 72.2% of its value, according to iSeeCars. Originally priced around $75,000, a 2020 model in average condition might only fetch $20,000 to $25,000 as a trade-in. Fix said this is due to rapid electric vehicle (EV) depreciation and low demand for Jaguar's aging design. Dealers hesitate to offer more because of high battery replacement costs and the brand's reputation for reliability issues. With a saturated used EV market and newer, more advanced electric models, the I-PACE's trade-in value is so low that owners should explore private sales or tax-deductible donations. Trending Now: The Maserati Levante, a luxury SUV, suffers from one of the highest depreciation rates in its class. According to CarEdge, it lost about 74% of its value after five years. Dealers are wary of the Levante's expensive maintenance and repairs, as well as Maserati's spotty reliability record, which further depresses its resale value. Fix said a 2019 Levante with an MSRP of $80,000 may only sell for $25,000 to $30,000, especially if it has considerable miles. For most owners, the trade-in offer will feel like a fraction of what the car once cost, making private sale, donation or keeping the car for personal use a smarter choice. The Nissan Leaf, once a pioneer in the electric vehicle market, now faces rapid depreciation due to outdated battery technology and limited range. According to CarEdge, the Nissan Leaf will 'depreciate 62% after 5 years' and have a '5-year resale value of $13,308.' The market for used Leafs is crowded, and dealers know that buyers prefer newer EVs with longer ranges, so they offer less to minimize their risk. For example, Fix said a 2020 model, initially $35,000, may only receive $10,000 to $12,000 in trade-in, a 60% loss in five years. Owners may find that selling privately or donating the car for a tax deduction will yield better value than accepting a dealer's lowball offer. The Chrysler 300, a full-size sedan once popular for its bold styling, now suffers from low demand and a poor resale reputation. According to iSeeCars, a new Chrysler 300 depreciates 52.1% after five years, resulting in a typical resale value of $16,422. Fix said excessive mileage (over 100,000 miles) or accident history can further reduce trade-in bids by 10 to 20%, frequently below private sale or trash value. Dealers are reluctant to pay more for a car that is difficult to resell, especially when factoring in reconditioning costs and the risk of sitting on unsold inventory. For many Chrysler 300 owners, trading in will not make sense financially, and exploring private sale options or keeping the car longer may be wiser. Auto mechanic and JustAnswer expert Chris Pyle suggests keeping the car if you need a spare or sell it online or from your front yard, rather than going to the dealership. According to Fix, Dodge Hornet was the slowest-selling new automobile, with a 299-day supply on dealer lots as of late 2024. She explains that an oversupply of slow-selling models, forces dealers to offer low trade-in values to clear lots. Moreover, CarEdge projects a Dodge Hornet will depreciate 65% after five years, with a three-year resale value of about $15,600, confirming the steep loss in value. Recent trade-in offers on CarMax show 2023 Dodge Hornets ranging from $21,000 to $24,000 for low-mileage vehicles. This means for higher-mileage or less desirable trims, trade-in values of $12,000 to $14,000 for a three-year-old model are realistic. Owners looking to maximize value should consider selling privately, donating for a tax deduction or holding onto the car until market conditions improve. Editor's note: Photos are for representational purposes only. More From GOBankingRates Mark Cuban Warns of 'Red Rural Recession' -- 4 States That Could Get Hit Hard 4 Housing Markets That Have Plummeted in Value Over the Past 5 Years 6 Hybrid Vehicles To Stay Away From in Retirement This article originally appeared on 5 Cars With Trade-In Values So Low That They're Not Worth Selling
